Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Accumulated Expenses: 2020-2025

  • China SXT Pharmaceuticals' Accumulated Expenses rose 11.77% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 11.77%. This contributed to the annual value of $2.9 million for FY2025, which is 6.11% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Accumulated Expenses stood at $3.3 million for Q3 2025, which was up 11.20% from $2.9 million recorded in Q1 2025.
  • China SXT Pharmaceuticals' Accumulated Expenses' 5-year high stood at $3.5 million during Q1 2022, with a 5-year trough of $2.8 million in Q1 2024.
  • Its 3-year average for Accumulated Expenses is $3.0 million, with a median of $3.0 million in 2023.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Accumulated Expenses skyrocketed by 36.71% in 2021 and then fell by 11.89% in 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $3.4 million in 2021, then dropped by 2.46% to $3.3 million in 2022, then fell by 0.89% to $3.2 million in 2023, then declined by 10.05% to $2.9 million in 2024, then rose by 11.77% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $2.9 million for Q1 2025, and $2.9 million during Q3 2024.